Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25354916 | 1.00 | MAPK1 (0.48) | MAPK1GPR119USP30TERTJAK2 | |
| SCHEMBL30453635 | 1.00 | MAPK1 (0.48) | MAPK1GPR119USP30TERTJAK2 | |
| SCHEMBL16640394 | 0.88 | MAPK1 (0.46) | MAPK1GPR119USP30RORC | |
| SCHEMBL27224152 | 0.88 | MAPK1 (0.46) | MAPK1GPR119USP30JAK2JAK1 | |
| SCHEMBL25224837 | 0.88 | MAPK1 (0.46) | MAPK1GPR119USP30JAK2JAK1 | |
| SCHEMBL31390800 | 0.86 | MAPK1 (0.45) | MAPK1GPR119USP30JAK2JAK1 | |
| SCHEMBL31390797 | 0.86 | MAPK1 (0.45) | MAPK1GPR119USP30JAK2JAK1 | |
| SCHEMBL26475785 | 0.86 | MAPK1 (0.45) | MAPK1GPR119USP30JAK2JAK1 | |
| SCHEMBL26102587 | 0.86 | MAPK1 (0.45) | MAPK1GPR119USP30JAK2JAK1 | |
| SCHEMBL4029061 | 0.85 | GSK3B (0.43) | MAPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | MAPK1 1677/4885GPR119 1537/4885USP30 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.